PPT-Target therapy for bone metastatic prostate cancer with Mic

Alexandre Iscaife Denis Reis Morais Sabrina Thalita Reis Nayara Izabel Viana Andre Bordini Daniele Janolli Nelson Dip Miguel Srougi Katia Ramos Moreira Leite Laboratory of Medical Research LIM 55 Urology University of Sao Paulo Sao Paulo Brazil. Prostate Cancer . Congress. Meeting in . a. Box. Screening for Prostate Cancer – . The PSA Controversy. Leonard G. . Gomella. , MD. US Preventive Services Task Force . (USPSTF) Screening Recommendations. Medical University of South Carolina . Charleston, SC. Bones, Hot Flashes, and ADT Use With Chemotherapy and Timing. Toxicities of ADT. Hot Flashes, sexual dysfunction and many other complications of therapy are seen in greater than 90% of men on ADT. ADVANCED PROSTATE CANCER: BONE ISSUES AND METASTASES Samuel Denmeade, MD Professor of Oncology, Urology and Pharmacology The Johns Hopkins University School of Medicine Castrate-sensitive Non-Metastatic Amar Mohee. Consultant Urological Surgeon. Manchester Royal Infirmary. Greater Manchester . Cancer. Prostate Cancer. Prostate . cancer: most . common cancer in . men. 47000/year (129 new diagnosis/day). Investigations for Prostate cancer Presentation: Diagnosis: Risk stratification (Ref) : Low risk PSA 0, Gleason score 6 (ISUP 1), DRE showing cT1 - T2a Intermediate risk: PSA 10 - 20, –. To treat . or not to treat. Dr Oliver Klein – Medical Oncologist. Prostate Cancer. |. . Epidemiology- Australia. Most common cancers 2012 . Cancer related deaths 2010 . Australian Institute of Health and Welfare. Azeez Farooki, MD. Attending Physician, Clinical Member. Memorial Sloan Kettering Cancer Center. New York, NY. Objectives. Elucidate the problem of aromatase inhibitor induced bone loss and increased risk of fractures in breast cancer. . Using PSMA-PET for accurate staging in biochemical recurrent metastatic prostate cancer. . Case courtesy of Associate Professor Yao ZHU, Fudan University, Shanghai Cancer Center. Photo by . Hobi. m. CSPC). 1. Neal Shore, MD, FACS. Carolina Urologic Research Center. Myrtle Beach, SC. Alicia Morgans, MD, MPH. Northwestern University. Chicago, IL. PROSTATE CANCER IS HORMONE DEPENDENT. 2. Huggins CB. Nobel lecture. Available from . Francesco GIAMMARILE. « . Aut tace aut loquere meliora silentio.  ». Bone scan and F-Choline . Radionuclide treatment . Presentation Outline. Introduction. NO CONFLICT OF INTEREST. General aspects. Foundation Medicine. ctDNA. is good information for somatic mutations in . mCRPC. when biopsy is not possible. lots of other data on the importance of CTCs as predictive. 93% concordance for BRCA1/2 for tissue and liquid biopsy – . Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Daniel P . Petrylak. , MD. . Disclosures for . Ms. . Sinibaldi. No financial interests or affiliations to disclose. Disclosures for Dr . Petrylak. Consulting Agreements. By: Ishan Parikh. Symptoms. Be on the look out for…. “stop-and-go” flow of urine. Sudden urges to urinate. Frequent urination (esp. at nights). Trouble starting urination. Trouble with emptying bladder completely. Jeanny B. Aragon-Ching, M.D., F.A.C.P.. Clinical Program Director of Genitourinary Cancers, Inova . Schar. Cancer Institute. Associate Professor of Medicine, Virginia Commonwealth University. October 13, 2018.